Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults

Dynamic Prediction of Treatment Response in Late-Life Depression

(2013) Ian Joel et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Serotonin–norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption

(2013) M. L. O. Shea et al.   OSTEOPOROSIS INTERNATIONAL

Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors

(2012) Eric J. Lenze et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Regulation of Bone Mass by Serotonin: Molecular Biology and Therapeutic Implications

(2011) Gerard Karsenty et al.   Annual Review of Medicine

Variants of the Serotonin Transporter Gene, Selective Serotonin Reuptake Inhibitors, and Bone Mineral Density in Risperidone-Treated Boys

(2011) Chadi A. Calarge et al.   JOURNAL OF CLINICAL PSYCHIATRY

Socioeconomic status, race, and bone turnover in the Midlife in the US Study

(2011) C. J. Crandall et al.   OSTEOPOROSIS INTERNATIONAL

Lrp5 and bone formation

(2010) Vijay K. Yadav et al.   Annals of the New York Academy of Sciences

Serotonin transporter gene-linked polymorphic region (5-HTTLPR) and diurnal cortisol: A sex by genotype interaction

(2010) Matthis Wankerl et al.   BIOLOGICAL PSYCHOLOGY

The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD

(2010) Geeta A Thakur et al.   BMC Psychiatry

Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels

(2010) Stuart J. Warden et al.   BONE

The Central Regulation of Bone Mass, The First Link between Bone Remodeling and Energy Metabolism

(2010) Gerard Karsenty et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update in Serotonin and Bone

(2010) Michael Bliziotes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Benefits and Limitations of Bone Mineral Density and Bone Turnover Markers to Monitor Patients Treated for Osteoporosis

(2010) E. Michael Lewiecki   Current Osteoporosis Reports

National Patterns in Antidepressant Medication Treatment

(2009) Mark Olfson et al.   ARCHIVES OF GENERAL PSYCHIATRY

The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5)

(2009) Stuart J. Warden et al.   BONE

Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening, prevention and management?

(2009) Elizabeth M. Haney et al.   BONE

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms

(2009) Alexandre Y. Dombrovski et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone turnover markers: understanding their value in clinical trials and clinical practice

(2009) R. Civitelli et al.   OSTEOPOROSIS INTERNATIONAL

Reduced hippocampal volumes associated with the long variant of the tri- and diallelic serotonin transporter polymorphism in major depression

(2008) Thomas Frodl et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

(2008) Vijay K. Yadav et al.   CELL

Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency

(2008) Stuart J. Warden et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation

(2007) C. Collet et al.   FASEB JOURNAL